Modifications of coronary risk factors

被引:19
作者
Albu, Jeanine
Gottlieb, Sheldon H.
August, Phyllis
Nesto, Richard W.
Orchard, Trevor J.
机构
[1] Hosp Columbia Univ, New York Obes Res Ctr, Coll Phys & Surg, New York, NY 10025 USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Cornell Univ, Weill Med Coll, New York, NY USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Univ Pittsburgh, Pittsburgh, PA 15260 USA
关键词
D O I
10.1016/j.amjcard.2006.03.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In addition to the revascularization and glycemic management interventions assigned at random, the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) design includes the uniform control of major coronary artery disease risk factors, including dyslipidemia, hypertension, smoking, central obesity, and sedentary lifestyle. Target levels for risk factors were adjusted throughout the trial to comply with changes in recommended clinical practice guidelines. At present, the goals are low-density lipoprotein cholesterol < 2.59 mmol/L (< 100 mg/dL) with an optional goal of < 1.81 mmol/L (< 70 mg/dL); plasma triglyceride level < 1.70 mmol/L (< ISO mg/dL); blood pressure level < 130 mm Hg systolic and < 80 mm Hg diastolic; and smoking cessation treatment for all active smokers. Algorithms were developed for the pharmacologic management of dyslipidemia and hypertension. Dietary prescriptions for the management of glycemia, plasma lipid profiles, and blood pressure levels were adapted from existing clinical practice guidelines. Patients with a body mass index > 2S were prescribed moderate caloric restriction; after the trial was under way, a lifestyle weight-management program was instituted. All patients were formally prescribed both endurance and resistance/flexibility exercises, individually adapted to their level of disability and fitness. Pedometers were distributed as a biofeedback strategy. Strategies to achieve the goals for risk factors were designed by BARI 2D working groups (lipid, cardiovascular and hypertension, and nonpharmacologic interventibn) and the ongoing implementation of the strategies is monitored by lipid, hypertension, and lifestyle intervention management centers. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:41G / 52G
页数:12
相关论文
共 64 条
[1]   UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes [J].
Adler, AI ;
Stevens, RJ ;
Neil, A ;
Stratton, IM ;
Boulton, AJM ;
Holman, RR .
DIABETES CARE, 2002, 25 (05) :894-899
[2]   The management of the obese diabetic patient [J].
Albu, J ;
Raja-Khan, N .
PRIMARY CARE, 2003, 30 (02) :465-+
[3]  
ALBU J, 2004, HDB OBESITY, P899
[4]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[5]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[6]  
[Anonymous], 1989, DIABETES CARE, V12, P573
[7]   The treatment of hypertension in adult patients with diabetes [J].
Arauz-Pacheco, C ;
Parrott, MA ;
Raskin, P .
DIABETES CARE, 2002, 25 (01) :134-147
[8]  
Arauz-Pacheco Carlos, 2004, Diabetes Care, V27 Suppl 1, pS65
[9]   Clinical outcomes in the diabetes cohort of the international verapamil SR-Trandolapril study [J].
Bakris, GL ;
Gaxiola, E ;
Messerli, FH ;
Mancia, G ;
Erdine, S ;
Cooper-DeHoff, R ;
Pepine, CJ .
HYPERTENSION, 2004, 44 (05) :637-642
[10]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869